Crinetics Pharmaceuticals Inc

Crinetics insider sales show routine tax‑cover moves, not a loss of confidence, as the company’s CT‑305 trial advances toward pivotal FDA milestones.

Crinetics insider trades reveal strategic divestment amid volatile stock and pending clinical milestones – key insights for cautious investors.